ENTERA BIO IS-0000769 (5DT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ENTERA BIO IS-0000769 (5DT) has a cash flow conversion efficiency ratio of -0.140x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.83 Million ≈ $-2.14 Million USD) by net assets (€13.10 Million ≈ $15.32 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ENTERA BIO IS-0000769 net asset quality index to measure how much of total assets are equity-financed.
ENTERA BIO IS-0000769 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how ENTERA BIO IS-0000769's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore 5DT operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
ENTERA BIO IS-0000769 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ENTERA BIO IS-0000769 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Alithya Group Inc
NASDAQ:ALYAF
|
0.010x |
|
Ipopema Securities SA
WAR:IPE
|
-3.010x |
|
Glomac Bhd
KLSE:5020
|
-0.010x |
|
China Tianrui Group Cement Company Limited
F:T18
|
0.021x |
|
NTT System SA
WAR:NTT
|
0.057x |
|
Lumos Diagnostics Holdings Ltd
AU:LDX
|
0.149x |
|
Lion Finance Group PLC
LSE:BGEO
|
0.071x |
|
PP Properti Tbk PT
JK:PPRO
|
0.001x |
Annual Cash Flow Conversion Efficiency for ENTERA BIO IS-0000769 (2021–2025)
The table below shows the annual cash flow conversion efficiency of ENTERA BIO IS-0000769 from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of ENTERA BIO IS-0000769.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €13.10 Million ≈ $15.32 Million |
€-7.37 Million ≈ $-8.62 Million |
-0.563x | +33.33% |
| 2024-12-31 | €8.08 Million ≈ $9.45 Million |
€-6.82 Million ≈ $-7.97 Million |
-0.844x | -19.89% |
| 2023-12-31 | €10.39 Million ≈ $12.14 Million |
€-7.31 Million ≈ $-8.55 Million |
-0.704x | +33.81% |
| 2022-12-31 | €11.75 Million ≈ $13.74 Million |
€-12.50 Million ≈ $-14.61 Million |
-1.063x | -164.76% |
| 2021-12-31 | €22.57 Million ≈ $26.38 Million |
€-9.06 Million ≈ $-10.60 Million |
-0.402x | -- |
About ENTERA BIO IS-0000769
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a ta… Read more